Johnson & Johnson (JNJ) to Withdraw Acid Reflux Treatment in Some Markets

Johnson & Johnson (NYSE:JNJ) is one of the best conservative stocks to buy now. On September 23, the company announced plans to withdraw the LINX Reflux Management System in certain countries.

The company has cited commercial reasons for withdrawing the device used to treat acid reflux disease. The withdrawal follows a thorough evaluation of market conditions and the ability to serve each market effectively. Likewise, the withdrawal is not related to any changes in the safety or efficacy of the device.

The LINX Reflux Management System was approved for patients struggling with chronic gastroesophageal reflux disease. The condition is associated with stomach content leaking backward into the esophagus.

Johnson & Johnson (NYSE:JNJ) engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It offers products for various therapeutic areas, including immunology, such as rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Performing Penny Stocks to Buy Now and 11 Best Healthcare Penny Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.